CN106728015A - 一种用于神经退行性疾病的中药制剂及其制备方法 - Google Patents
一种用于神经退行性疾病的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN106728015A CN106728015A CN201611114561.XA CN201611114561A CN106728015A CN 106728015 A CN106728015 A CN 106728015A CN 201611114561 A CN201611114561 A CN 201611114561A CN 106728015 A CN106728015 A CN 106728015A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- degenerative diseases
- nerve degenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 210000005036 nerve Anatomy 0.000 title claims abstract description 36
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 23
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims abstract description 22
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000021286 stilbenes Nutrition 0.000 claims abstract description 22
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 17
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 17
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 14
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 14
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 12
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 12
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 12
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 12
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 12
- 241000132012 Atractylodes Species 0.000 claims abstract description 11
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 11
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 11
- 241000756943 Codonopsis Species 0.000 claims abstract description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 11
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 235000005412 red sage Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- 238000009423 ventilation Methods 0.000 claims description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 230000003712 anti-aging effect Effects 0.000 abstract description 5
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 4
- 239000009636 Huang Qi Substances 0.000 abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 abstract description 4
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 15
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000006931 brain damage Effects 0.000 description 7
- 231100000874 brain damage Toxicity 0.000 description 7
- 208000029028 brain injury Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000001178 neural stem cell Anatomy 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000006278 hypochromic anemia Diseases 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241001566735 Archon Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000214032 Hedysarum Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 241000219991 Lythraceae Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical group [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于神经退行性疾病的中药制剂及其制备方法,其主要由以下重量份的原料药制成:乌药8‑12份、首乌8‑12份,银杏叶8‑14份、红芪8‑12份、黄芪8‑12份、石榴皮8‑12份、丹参6‑10份、川芎3‑6份、党参3‑6份、白术3‑5份、地龙3‑5份、红花3‑5、莲子3‑5份。该发明用于神经退行性疾病及神经再生,具有优良的促神经再生作用,并具有延缓衰老、抗动脉硬化和脑缺血等作用,具有疗效显著、无副作用,标本兼治,成本低的优点。
Description
技术领域
本发明属于中药技术领域,具体涉及一种用于神经退行性疾病的中药制剂及其制备方法。
背景技术
神经退行性疾病主要包括中风、缺血性痴呆、阿尔茨海默病、帕金森病以及脑外伤等,具有致残率高、死亡率高、复发率高以及并发症多的特点。脑损伤后早期一般都伴随脑内神经元缺失、意识、语言、肢体功能以及学习记忆能力下降等症状。后遗症期主要表现为病情平稳,失去的功能不再有明显好转。中药及其有效成分常用于脑损伤及神经退行性疾病的治疗。中药及其有效成分不仅可以在脑损伤早期改善血液循环,保护神经细胞及提高神经元的抗损伤能力,对于脑损伤恢复期及后遗症的治疗也具有明确的疗效。
近年研究表明,成年动物或人中枢神经系统多区域存在着具有多向分化潜能的神经干细胞,至少在几个确定的区域内神经再生贯穿整个生命过程。神经干细胞具有自我更新,多潜能分化等特点,可以补充替代损伤的神经细胞,为神经损伤修复提供了新策略。然而在正常情况下脑内神经干细胞的数目太少,中枢神经系统内神经再生的发生频率很低。虽然几种伤害性刺激,比如缺血、外伤、神经变性等能够引起内源性神经干细胞的增殖,但新生的神经干细胞数目较少,神经分化比例也较低,并不足以产生自我修复效果。这就使人们不得不寄希望于通过外源性干预促进脑损伤后神经再生。基于神经干细胞的神经再生过程主要涉及以下几个步骤:(1)通过不断自我更新和增殖获得足够数目的神经干细胞以补充缺失的组织细胞;(2)通过使神经干细胞向特定类型的神经细胞诱导分化以补充脱失的神经细胞;(3)通过促进新生的神经细胞存活并建立功能性联系以达到促进神经功能重建的目的。
现有的神经退行性疾病治疗药物普遍存在治疗效果差,药物费用高等缺陷,严重制约了对患者治疗的效果加重了患者的负担。
祖国医学在治疗脑损伤及神经退行性疾病方面具有丰富的理论知识和临床经验,结合现代医学对神经损伤修复关键环节的认识,可以从中药及其有效成分中快速发现治疗神经损伤疾病的药物。
中医药在神经退行性疾病治疗方面积累大量的中医理论和临床实践,具有潜在的优势和广阔的开发前景。因此提供一种能够治疗认知障碍的中药已成为当务之急。
发明内容
针对目前医学实践中缺少神经退行性疾病显效治疗药物、且药物价格高昂的现有技术不足,本发明提供一种用于神经退行性疾病的中药制剂。该中药制剂用于神经退行性疾病及神经再生,疗效显著,成本低廉,具有良好的医学应用前景。
本发明的第一个目的在于提供一种用于神经退行性疾病的中药制剂。本发明中药制剂由以下重量份的原料药制得:乌药8-12份、首乌8-12份,银杏叶8-14份、红茋8-12份、黄茋8-12份、石榴皮8-12份、丹参6-10份、川芎3-6份、党参3-6份、白术3-5份、地龙3-5份、红花3-5、莲子3-5份。
进一步地,本发明中药制剂由以下重量份的原料药制得:乌药9-11份、首乌9-11份,银杏叶9-13份、红茋9-11份、黄茋9-11份、石榴皮9-11份、丹参7-9份、川芎4-5份、党参4-5份、白术4-5份、地龙4-5份、红花4-5、莲子4-5份。
更进一步地,本发明中药制剂由以下重量份的原料药制得:乌药10份、首乌10份,银杏叶12份、红茋10份、黄茋10份、石榴皮10份、丹参8份、川芎5份、党参5份、白术5份、地龙5份、红花5、莲子5份。
本发明配方的原料药中,其中乌药为樟科植物乌药的干燥块根。全年均可采挖,除去细根,洗净,趁鲜切片,晒干,或直接晒干。《药品化义》中记载“乌药,气雄性温,故快气宣通,疏散凝滞,甚于香附。外解表而理肌,内宽中而顺气。以之散寒气,则客寒冷痛自除;驱邪气则天行疫瘴即却;开郁气,中恶腹痛,胸膈胀满,顿然可减;疏经气,中风四肢不遂,初产血气凝滞,渐次能通,皆藉其气雄之功也。”
首乌又名何首乌,性温,味苦、甘、涩,入肝、肾经。制首乌为滋补良药,具有补肝肾、益精血、乌须发、强筋骨等功能,可用于血虚萎黄、眩晕耳呜、须发早白、腰膝酸软、肢体麻木。现代药理研究表明,首乌具有延缓衰老、抗动脉硬化和脑缺血等作用。
首乌中含有活性成分二苯乙烯苷具有脑保护作用;能够改善缺血再灌注所导致的沙土鼠学习记忆功能障碍,并对多种拟痴呆细胞模型有神经保护作用;对实验性动脉粥样硬化大鼠血脂和炎症因子也有调节作用。
首乌是中医药治疗脑缺血中风和老年痴呆的常用中药,成分和功效已相对明确。首乌活血功能不强,影响疗效。佐以活血类中药,将能显著提高药效。
银杏叶,性平、味甘、苦、涩,归心、肺经。具有活血化瘀、止痛之功效,用于冠心病、心绞痛、高脂血症。银杏的主要有效成分为银杏酮酯和黄酮。其制剂杏灵颗粒、金纳多片等具有活血化瘀、通脉舒络之功能,主要用于血瘀引起的卒中、胸痹(冠心病)等症,症见:胸闷心悸、舌强语蹇、半身不遂、偏身麻木、口舌歪斜、痴呆等。但单一银杏叶提取物制剂因毒性成分银杏酸的存在而使其使用受到限制,其药效和疗效仍有待进一步提高。
长期研究发现,首乌配伍银杏叶,促进神经再生和改善学习记忆作用显著增强。首乌和银杏叶合用时,二苯乙烯苷等活性成分加快进入脑组织,并增加它们在脑组织中浓度和生物利用度。
银杏黄酮成分能促进首乌活性成分二苯乙烯苷进入脑组织发挥作用。增强促进神经再生和改善学习记忆的药效。
红芪具有补气升阳,固表止汗,利水消肿,生津养血,行滞通痹,托毒排脓,敛疮生肌之功效。常用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,内热消渴,血虚萎黄,半身不遂,痹痛麻木,痈疽难溃,久溃不敛。红芪含红芪多糖,能显著促进巨噬细胞活性,提高免疫功能,明显降低血浆过氧化脂质的含量,提升白球蛋白比值,促进RNA合成,此外,红芪尚能改善肺的摄氧功能。实验证实其对雪旺氏细胞有较好的促生长作用,也有对周围神经损伤后的修复与再生作用。
黄芪有强化机体的作用,现代医学研究表明,黄芪有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。能消除实验性肾炎蛋白尿,增强心肌收缩力,调节血糖含量。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。
石榴皮为石榴科植物石榴的干燥果皮。石榴皮性酸、味涩,在我国传统医药中主要用于久泻、出血等证。石榴皮中的多酚是一类具有多酚羟基化合物的总称,包括鞣花单宁、没食子单宁、鞣花酸、没食子酸等多种化合物,含量约为其干质量的10%-20%,具有抗菌、抗氧化、抗衰老、抗癌防癌、降血压和预防心脑血管疾病等多种生理和药理活性。
丹参具有活血散淤、消肿止血、消炎止痛、调经止痛、扩张冠状动脉、改善心肌缺血状况、降低血压、安神静心、降血糖和抗菌等功效,对月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛等病症有一定的疗效。此外,近代医学实验证明,丹参还具有抗血小板凝聚、降低血液黏度及调节内外凝血系统的功能,是一种安全又可靠的治疗心脏血管疾病的天然中药。
川芎,原名芎藭。一种中药植物,常用于活血行气,祛风止痛,主要栽培于四川、云南、贵州、广西、湖北等地。川芎辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。活血祛瘀作用广泛,适宜瘀血阻滞各种病症;祛风止痛,效用甚佳,可治头风头痛、风湿痹痛等症。昔人谓川芎为血中之气药,殆言其寓辛散、解郁、通达、止痛等功能。本品辛温升散,凡阴虚阳亢及肝阳上亢者不宜应用;月经过多、孕妇亦忌用。川芎亦含阿魏酸,具有改善微循环,降压扩血管,抑制血小板聚集的功能。
党参,具有补中益气,健脾益肺的功效,可促进DNA的合成和糖解,有提高能量代谢和蛋白质合成及补元气,固脱生津的的作用。
白术对血小板聚集有明显的抑制作用。
地龙提取物降血压,地龙还含血栓溶解素,能直接催化纤溶蛋白酶类,抑制血栓形成。
红花,活血祛瘀,能扩张血管,且能抑制血栓形成。
莲子具有补脾止泻,止带,益肾涩精,养心安神之功效。
本发明中药制剂可以采用中药制剂的常规方法制备成常规的制剂,例如将原料药进行水煎,或精制成中药提取物。
本发明的另一个目的在于提供上述中药制剂的制备方法,包括如下步骤:
步骤1)按照组方配比进行称量,将各组方药材洗净,切段,于通风处晾干;
步骤2)将步骤1制得的药材加入与其总重量比为1∶5-15:的水中浸泡半小时,煎煮2-3次,每次3小时;
步骤3)将步骤2中的提取液过滤后静置5小时,再次过滤,加热浓缩至所需体积,获得水提浸膏,干燥后,采用气流粉碎的方法粉碎成15-20微米的超细粉;
步骤4)将步骤3中的超细粉混合均匀,制成复方合剂。
其中,步骤2中的水为温度5-35℃的蒸馏水。
步骤2中的煎煮为先武火煮沸0.5小时而后改文火煎煮2.5小时。
步骤4中制备成的复方合剂为制成袋装中药剂或制成软质胶囊。
本发明的有益效果是:
1)本发明用于神经退行性疾病及神经再生,具有优良的促神经再生作用,并具有延缓衰老、抗动脉硬化和脑缺血等作用,具有疗效显著、无副作用,标本兼治,成本低的优点。
2)本发明有利于神经细胞修复,能够增加缺血区新生血管,改善脑供血,促进神经功能恢复。
3)本发明中药起效剂量低,并可以制备成不同的给药剂型和给药剂量,可以根据患者疾病的严重程度选用合适的给药方案,从而可以大大提高患者的用药依从性,提高药物使用的长期效果。
具体实施方式
实施例1
一种用于神经退行性疾病的中药制剂,其主要由以下重量份的原料药制得:乌药8份、首乌8份,银杏叶8份、红茋8份、黄茋8份、石榴皮8份、丹参6份、川芎3份、党参3份、白术3份、地龙3份、红花3、莲子3份。
上述中药制剂的制备方法,包括如下步骤:
步骤1)按照组方配比进行称量,将各组方药材洗净,切段,于通风处晾干;
步骤2)将步骤1制得的药材加入与其总重量比为1∶5-15:的温度5-35℃的蒸馏水中浸泡半小时,煎煮2-3次,每次先武火煮沸0.5小时而后改文火煎煮2.5小时;
步骤3)将步骤2中的提取液过滤后静置5小时,再次过滤,加热浓缩至所需体积,获得水提浸膏,干燥后,采用气流粉碎的方法粉碎成15-20微米的超细粉;
步骤4)将步骤3中的超细粉混合均匀,制成袋装中药剂或制成软质胶囊。
实施例2
本发明中药制剂由以下重量份的原料药制得:乌药10份、首乌10份,银杏叶12份、红茋10份、黄茋10份、石榴皮10份、丹参8份、川芎5份、党参5份、白术5份、地龙5份、红花5、莲子5份。
上述中药制剂的制备方法,包括如下步骤:
步骤1)按照组方配比进行称量,将各组方药材洗净,切段,于通风处晾干;
步骤2)将步骤1制得的药材加入与其总重量比为1∶5-15:的温度5-35℃的蒸馏水中浸泡半小时,煎煮2-3次,每次先武火煮沸0.5小时而后改文火煎煮2.5小时;
步骤3)将步骤2中的提取液过滤后静置5小时,再次过滤,加热浓缩至所需体积,获得水提浸膏,干燥后,采用气流粉碎的方法粉碎成15-20微米的超细粉;
步骤4)将步骤3中的超细粉混合均匀,制成袋装中药剂或制成软质胶囊。
实施例3
本发明中药制剂由以下重量份的原料药制得:12份、首乌12份,银杏叶14份、红茋12份、黄茋12份、石榴皮12份、丹参10份、川芎6份、党参6份、白术5份、地龙5份、红花5、莲子5份。
上述中药制剂的制备方法,包括如下步骤:
步骤1)按照组方配比进行称量,将各组方药材洗净,切段,于通风处晾干;
步骤2)将步骤1制得的药材加入与其总重量比为1∶5-15:的温度5-35℃的蒸馏水中浸泡半小时,煎煮2-3次,每次先武火煮沸0.5小时而后改文火煎煮2.5小时;
步骤3)将步骤2中的提取液过滤后静置5小时,再次过滤,加热浓缩至所需体积,获得水提浸膏,干燥后,采用气流粉碎的方法粉碎成15-20微米的超细粉;
步骤4)将步骤3中的超细粉混合均匀,制成袋装中药剂或制成软质胶囊。
治疗范围:
主要治疗神经退行性疾病如中风、缺血性痴呆、阿尔茨海默病、帕金森病以及脑外伤等或用于神经再生,对于脑损伤恢复期及后遗症的治疗也具有明确的疗效。
用法用量:
初服每日三次,每次饭后服用30-50克,稳定后减至每日一次。一个月为一疗程,最少三个疗程,最多六个疗程。
实验观察一般资料:
前后共实验病人74例,其中中风36人,年龄55-72岁;缺血性痴呆38人,年龄50-70岁。服用本发明要后,病情均明显减轻。
治疗方法:
所有74例病人在自愿的情况下,服用本药剂,每日三次,每次饭后服用30-50克。一个月为一疗程,服用四个疗程。
结果分析:
所有74例病人中病情均有显著减轻,治疗效果明显。
本发明所述的一种用于神经退行性疾病的中药制剂及其制备方法并不仅仅局限于上述实施例,凡是依据本发明原理的任何改进或替换,均应在本发明的保护范围之内。
Claims (7)
1.一种用于神经退行性疾病的中药制剂,其特征在于,其主要由以下重量份的原料药制成:乌药8-12份、首乌8-12份,银杏叶8-14份、红茋8-12份、黄茋8-12份、石榴皮8-12份、丹参6-10份、川芎3-6份、党参3-6份、白术3-5份、地龙3-5份、红花3-5、莲子3-5份。
2.根据权利要求1所述的一种用于神经退行性疾病的中药制剂,其特征在于,乌药9-11份、首乌9-11份,银杏叶9-13份、红茋9-11份、黄茋9-11份、石榴皮9-11份、丹参7-9份、川芎4-5份、党参4-5份、白术4-5份、地龙4-5份、红花4-5、莲子4-5份。
3.根据权利要求1所述的一种用于神经退行性疾病的中药制剂,其特征在于,乌药10份、首乌10份,银杏叶12份、红茋10份、黄茋10份、石榴皮10份、丹参8份、川芎5份、党参5份、白术5份、地龙5份、红花5、莲子5份。
4.根据权利要求1或2或3所述的用于神经退行性疾病的中药制剂的制备方法,其特征在于,包括如下步骤:
步骤1)按照组方配比进行称量,将各组方药材洗净,切段,于通风处晾干;
步骤2)将步骤1制得的药材加入与其总重量比为1∶5-15:的水中浸泡半小时,煎煮2-3次,每次3小时;
步骤3)将步骤2中的提取液过滤后静置5小时,再次过滤,加热浓缩至所需体积,获得水提浸膏,干燥后,采用气流粉碎的方法粉碎成15-20微米的超细粉;
步骤4)将步骤3中的超细粉混合均匀,制成复方合剂。
5.根据权利要求4所述的一种用于神经退行性疾病的中药制剂的制备方法,其特征在于,所述步骤2中的水为温度5-35℃的蒸馏水。
6.根据权利要求4所述的一种用于神经退行性疾病的中药制剂的制备方法,其特征在于,所述步骤2中的煎煮为先武火煮沸0.5小时而后改文火煎煮2.5小时。
7.根据权利要求4所述的一种用于神经退行性疾病的中药制剂的制备方法,其特征在于,所述步骤4中制备成的复方合剂为制成袋装中药剂或制成软质胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611114561.XA CN106728015A (zh) | 2016-12-07 | 2016-12-07 | 一种用于神经退行性疾病的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611114561.XA CN106728015A (zh) | 2016-12-07 | 2016-12-07 | 一种用于神经退行性疾病的中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106728015A true CN106728015A (zh) | 2017-05-31 |
Family
ID=58874737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611114561.XA Pending CN106728015A (zh) | 2016-12-07 | 2016-12-07 | 一种用于神经退行性疾病的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106728015A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700068608A1 (it) * | 2017-06-20 | 2018-12-20 | Neilos S R L | Composizione per trattamento o prevenzione di una malattia neurodegenerativa |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102233009A (zh) * | 2011-06-21 | 2011-11-09 | 广东药学院 | 一种促进神经再生的中药组合物及其制备方法和应用 |
CN102762573A (zh) * | 2009-07-24 | 2012-10-31 | 阿马曾提斯公司 | 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法 |
CN103182012A (zh) * | 2013-02-07 | 2013-07-03 | 洛阳市洛铜医院 | 一种治疗缺血性脑中风的药物及其制备方法 |
CN103989912A (zh) * | 2014-06-19 | 2014-08-20 | 杨献华 | 用于缺血性脑卒中后神经再生的中药组合物及其制备方法 |
CN104547162A (zh) * | 2013-10-18 | 2015-04-29 | 耿文杰 | 一种治疗中风偏瘫的中药 |
-
2016
- 2016-12-07 CN CN201611114561.XA patent/CN106728015A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102762573A (zh) * | 2009-07-24 | 2012-10-31 | 阿马曾提斯公司 | 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法 |
CN102233009A (zh) * | 2011-06-21 | 2011-11-09 | 广东药学院 | 一种促进神经再生的中药组合物及其制备方法和应用 |
CN103182012A (zh) * | 2013-02-07 | 2013-07-03 | 洛阳市洛铜医院 | 一种治疗缺血性脑中风的药物及其制备方法 |
CN104547162A (zh) * | 2013-10-18 | 2015-04-29 | 耿文杰 | 一种治疗中风偏瘫的中药 |
CN103989912A (zh) * | 2014-06-19 | 2014-08-20 | 杨献华 | 用于缺血性脑卒中后神经再生的中药组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
俞学海: "川芎防治脑中风的现状与前景", 《中西医结合心脑血管病杂志》 * |
纪白慧,等,: "石榴皮抗氧化活性成分的提取及其组分的研究", 《天然产物研究与开发》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700068608A1 (it) * | 2017-06-20 | 2018-12-20 | Neilos S R L | Composizione per trattamento o prevenzione di una malattia neurodegenerativa |
WO2018235016A1 (en) * | 2017-06-20 | 2018-12-27 | Neilos S.r.l. | COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISEASE |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
CN103040715A (zh) | 一种美容护肤用中药组合物 | |
CN103751633A (zh) | 一种治疗下肢静脉曲张的中药组合物及其制备方法 | |
CN104013868A (zh) | 一种治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN107596197A (zh) | 一种补气解郁茶及其制备方法 | |
CN106880826A (zh) | 一种治疗慢性心力衰竭的中药制剂及其制备方法 | |
CN106421194A (zh) | 一种筋骨调理液及其制备方法 | |
CN103599409B (zh) | 一种治疗三叉神经痛的中药组合物 | |
CN106728015A (zh) | 一种用于神经退行性疾病的中药制剂及其制备方法 | |
CN102846113B (zh) | 一种桑叶保健枕芯及其制备方法 | |
CN108815015A (zh) | 一种眼膜及其生产工艺 | |
CN108567852A (zh) | 一种防治糖尿病神经病变的药物组合物 | |
CN101485875A (zh) | 一种防治脱发药物组方及其制备方法 | |
CN105560894A (zh) | 一种治疗过敏性唇炎的中药组合物及制备方法 | |
CN105055856B (zh) | 一种治疗心脑血管疾病的茶色素中药组合物及其制备方法和用途 | |
CN104367896B (zh) | 一种治疗气虚血瘀型中风的药物组合物及其制备方法 | |
CN104352866A (zh) | 一种治疗火毒伤津型烧伤的中药制剂及其制备方法 | |
CN104055900A (zh) | 一种治疗荨麻疹的中药组合物 | |
CN102872210B (zh) | 一种治疗荨麻疹的中药 | |
CN102357157B (zh) | 一种治疗皮肤痤疮伴有螨虫感染的中药组合物 | |
CN106421647A (zh) | 净身排毒的瑶药外用桶浴药液及其制备方法 | |
CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
CN105362706A (zh) | 金钗石斛清热凉茶 | |
CN104189192B (zh) | 治疗荨麻疹的中药药浴及制备方法 | |
CN104258301A (zh) | 一种治疗女性更年期室性早搏的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |
|
WD01 | Invention patent application deemed withdrawn after publication |